PROCEPT BioRobotics (PRCT) Receives a Hold from BTIG

BTIG analyst Ryan Zimmerman maintained a Hold rating on PROCEPT BioRobotics (PRCT – Research Report) yesterday. The company’s shares closed yesterday at $60.61.

Zimmerman covers the Healthcare sector, focusing on stocks such as Vericel, Intuitive Surgical, and Penumbra. According to TipRanks, Zimmerman has an average return of 9.6% and a 47.47% success rate on recommended stocks.

PROCEPT BioRobotics has an analyst consensus of Strong Buy, with a price target consensus of $61.00.

PRCT market cap is currently $3.12B and has a P/E ratio of -26.99.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PRCT in relation to earlier this year. Most recently, in March 2024, Kevin Waters, the EVP, CFO of PRCT bought 53,757.00 shares for a total of $243,691.52.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

PROCEPT BioRobotics (PRCT) Company Description:

PROCEPT BioRobotics Corp is a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology.